Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, CON ENMASCARAMIENTO PARA LOS EVALUADORES DE LA EFICACIA DE RISANKIZUMAB EN COMPARACIÓN CON USTEKINUMAB PARA EL TRATAMIENTO DE SUJETOS ADULTOS CON ENFERMEDAD DE CROHN DE MODERADA A GRAVE SIN RESPUESTA AL TRATAMIENTO CON TERAPIA ANTI-TNF.
ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, CON ENMASCARAMIENTO PARA LOS EVALUADORES DE LA EFICACIA DE RISANKIZUMAB EN COMPARACIÓN CON USTEKINUMAB PARA EL TRATAMIENTO DE SUJETOS ADULTOS CON ENFERMEDAD DE CROHN DE MODERADA A GRAVE SIN RESPUESTA AL TRATAMIENTO CON TERAPIA ANTI-TNF.
Datos básicos
- Protocolo:
- M20-259
- EUDRACT:
- 2020-002674-26
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2020
- Año de finalización:
- 2024
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
Adherence to diagnostic and treatment recommendations for the management of acute severe ulcerative colitis: a prospective and multinational study
Rodriguez-Lago, I.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU
Ballester Ferre, M. P.; (...); Minguez, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.727. 2021
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers.
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.3748/wjg.v29.i7.1139. 2023
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Association between Chronotype, Physical Activity and Sedentary Behaviour: A Systematic Review
Sempere-Rubio, Nuria, Aguas, Mariam, Faubel, Raquel
Article. 10.3390/ijerph19159646. 2022
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Taxonera, Carlos; (...); Alba, Cristina
Article. 10.1111/apt.16964. 2022
Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis
Taxonera Samso, C.; (...); Alba, C.
Meeting Abstract. 2022
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Catalase inhibition can modulate the ability of peripheral blood T cells to undergo apoptosis in Crohn's disease.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.1093/cei/uxad134. 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat, Margalida; (...); Domenech, Eugeni
Article. 10.1177/17562848231221713. 2024
Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations.
Ricart E; (...); González-Lama Y
Article. 10.1093/crocol/otae055. 2024
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry
Madero Velazquez, L.; (...); Gutierrez-Casbas, A.
Meeting Abstract. 2024
Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry
Gonzalez Munoza, C.; (...); Garcia-Planella, E.
Meeting Abstract. 2022
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensus
Gonzalez Lama, Y.; (...); Munoz, F.
Meeting Abstract. 2023
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab242. 2021
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
Aguas Peris, M.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0428. 2025
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.1016/j.gastrohep.2021.08.006. 2021
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Del Hoyo Francisco, J.; (...); Aguas, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.758. 2021
Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn's disease
Ladron Abia, P.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.537. 2021
Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources
Sempere Robles, L.; (...); Ruiz, M. T.
Article. 2022
Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown
Sempere Robles, L.; (...); van-der Hofstadt, C.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.270. 2021
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2024
Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2023
Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study
Frasson, M.; (...); Pellino, G.
Meeting Abstract. 2023
Efectiveness And Safety Of Ustekinumab In Elderly Patients With Crohn's Disease: Real World Evidence From The Eneida Registry.
Casas-Deza, Diego; (...); Garcia-Lopez, Y Santiago
Article. 10.1093/ecco-jcc/jjac108. 2022
Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.
Guardiola Capon, J.; (...); Rodriguez-Moranta, F.
Meeting Abstract. 2024
Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Garcia, M. J.; (...); Chaparro, M.
Meeting Abstract. 2023
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
Garcia, Maria Jose; (...); Chaparro, Maria
Article. 10.1111/apt.17938. 2024
Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
Teresa VD; (...); Federico, Arguelles-Arias
Article. 10.1177/17562848231153560. 2023
Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
Chaparro, Maria; (...); Lázaro Pérez-Calle, José
Article. 10.1093/ecco-jcc/jjab070. 2021
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effectiveness of Upadacitinib in Patients with Baseline Active Extraintestinal Manifestations and Inflammatory Bowel Disease. A multicenter retrospective study
Fuentes-Valenzuela, E.; (...); Barrio, J.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1180. 2025
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial.
Ginard, Daniel; (...); Sans, Miquel
Article. 10.1159/000540792. 2024
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity.
Guijarro LG; (...); Hernández-Breijo B
Article. 10.3390/biomedicines10030727. 2022
Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment
Sanchis-Artero, L; (...); Cortes-Rizo, X
Article. 10.1038/s41598-021-88823-2. 2021
Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Article. 10.1016/j.gastrohep.2023.12.001. 2024
Evolution of the emotional impact in patients with early inflammatory bowel disease during and after Covid-19 lockdown.
Sempere L; (...); Hofstadt CV
Article. 10.1016/j.gastrohep.2021.03.004. 2021
Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project.
Orejudo, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia.
Huguet JM; (...); Paredes JM
Article. 10.3390/jcm11102786. 2022
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study.
Sempere L; (...); Ruiz-Cantero MT
Article. 10.1093/ibd/izad001. 2023
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
Calafat M; (...); Domènech E
Article. 10.14309/ajg.0000000000002965. 2024
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
Giordano, Antonio; (...); ENEIDA project of GETECCU
Article. 10.14309/ajg.0000000000003207. 2025
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.
Gutiérrez A; (...); Francés R
Article. 10.3389/fmed.2022.823900. 2022
Immunoepigenetic Regulation of Inflammatory Bowel Disease: Current Insights into Novel Epigenetic Modulations of the Systemic Immune Response.
Bastida, Guillermo; (...); Moret-Tatay, Ines
Article. 10.3390/genes14030554. 2023
Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review.
Quesada-Simo, A.; (...); Gil-Perotin, S.
Article. 10.3389/fphar.2023.1186016. 2023
Impact of telemonitoring on the management of Inflammatory Bowel Disease in Spain: a multicenter TECCU clinical trial
Peris, M. Aguas; (...); Nos, P.
Meeting Abstract. 2023
Incidence and risk factors of infection in patients with inflammatory bowel disease: longitudinal prospective INFEII registry of GETECCU
Zabana, Y.; (...); Esteve, M.
Meeting Abstract. 2024
Incidence of opioid-induced esophageal dysfunction.
Abia, Pablo Ladron; (...); Garrigues, Vicente
Article. 10.1016/j.gastrohep.2022.05.004. 2022
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
Chaparro, Maria; (...); Gisbert, Javier P.
Article. 10.3390/jcm10132885. 2021
Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
Barreiro-de Acosta, M; (...); Nos, P
Article. 10.1002/ueg2.12105. 2021
Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
Gonzalez Vivo, M.; (...); Marquez, L.
Meeting Abstract. 2022
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.
Gonzalez-Munoza, Carlos; (...); Domenech, Eugeni
Article. 10.1093/postmj/qgae076. 2024
Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Chetwood, John David; (...); Leong, Rupert W
Article. 10.1093/ecco-jcc/jjae059. 2024
Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
Pérez de Arce E; (...); Nos P
Article. 10.1016/j.gastrohep.2021.02.022. 2021
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Leishmania infection in patients with inflammatory bowel disease: Case series and literature review.
Gimeno-Pitarch L, Almela P, Nos P
Article. 10.1016/j.gastrohep.2023.04.001. 2024
Letter to the Editor on The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.
Gutierrez-Ontalvilla P; (...); Iborra M
Article. 10.1007/s00266-022-02960-1. 2022
Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn's Disease. Data from the ENEIDA registry
Pinero, G. S.; (...); Domenech, E.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0794. 2025
Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
Acosta MB; (...); Rodríguez-Lago I
Article. 10.14309/ajg.0000000000002152. 2023
Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
Gargallo-Puyuelo, C.; (...); Gomollon, F.
Meeting Abstract. 2023
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Article. 10.1002/jca.22101. 2023
Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain.
Calvet X; (...); Barreiro-de Acosta M
Article. 10.1093/ecco-jcc/jjac068. 2022
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
Zabana Y; (...); Esteve M
Article. 10.3390/jcm11020421. 2022
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Ferreiro-Iglesias, Rocio; (...); Barreiro-de Acosta, Manuel
Article. 10.1111/apt.18133. 2024
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Novel biomarkers associated with inflammatory bowel disease
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world
Minguez, A.; (...); Bastida, G.
Meeting Abstract. 2024
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
Minguez, Alejandro; (...); Bastida, Guillermo
Article. 10.1016/j.gastrohep.2024.502253. 2024
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.
Riestra S; (...); Domènech E
Article. 10.3390/jcm11133915. 2022
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU.
Casanova, Maria Jose; (...); Gisbert, Javier P
Article. 10.1016/j.dld.2024.05.009. 2024
Personalised therapy in inflammatory bowel disease
Calderón P; (...); Quera R
Article. 10.1016/j.gastrohep.2023.12.006. 2024
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease.
Calvo Moya M; (...); Gutiérrez Casbas A
Article. 10.1016/j.gastrohep.2023.12.013. 2024
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
D'Haens, G.; (...); Laharie, D.
Meeting Abstract. 2023
Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease
Soleto, I.; (...); Chaparro, M.
Meeting Abstract. 2023
Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery
Baldan-Martin, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
Sanz Segura, Patricia; (...); Garcia-Lopez, Santiago
Article. 10.1016/j.dld.2024.05.021. 2024
Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients.
Bernabeu P; (...); Sempere L
Article. 10.3389/fpsyg.2024.1334308. 2024
Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD
Bernabeu, P.; (...); Sempere, L.
Article. 2022
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain
Hernandez Camba, A.; (...); Barreiro, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.312. 2021
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
Hernandez Camba, Alejandro; (...); Barreiro-de Acosta, Manuel
Article. 10.1016/j.gastrohep.2021.08.007. 2021
Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis
Llao, J.; (...); Moral, E. Domenech
Meeting Abstract. 2023
Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2023
Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease.
Huguet, JM; (...); Paredes, JM
Article. 10.12998/wjcc.v9.i36.11285. 2021
Real-world effectiveness of vedolizumab in managing refractory pouchitis: a multicenter study on intravenous to subcutaneous transition
Gimeno-Pitarch, L.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1018. 2025
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
Iborra, Marisa; (...); Nos, Pilar
Article. 10.1080/00365521.2023.2278427. 2023
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
Barreiro-de Acosta, M.; (...); Ferreiro-Iglesias, R.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0783. 2025
Real-world subcutaneous infliximab for inflammatory bowel disease: A systematic review and meta-analysis
Chetwood, J.; (...); Leong, R.
Meeting Abstract. 2023
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.
Hernandez-Camba, A.; (...); GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)
Article. 10.1016/j.dld.2021.10.002. 2021
Recommendations of the Valencian Society of Digestive Pathology for the use of telemedicine and non-contact consultations.
Jover, Rodrigo; (...); Nos, Pilar
Article. 10.1016/j.gastrohep.2021.04.009. 2022
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved.
Guijarro, Luis G.; (...); On Behalf Of The Predicrohn Study Group From Geteccu
Article. 10.1016/j.biopha.2021.112239. 2021
Relevance of Clinical Cases.
Balaguer, Francesc; (...); Saez Gonzalez, Esteban
Editorial Material. 10.1016/j.gastrohep.2022.02.001. 2022
Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
Calafat M; (...); ENEIDA Study Group of GETECCU
Article. 10.1093/ecco-jcc/jjab213. 2021
Role of Interleukin-8 in Predicting Long-Term Response to Vedolizumab in Ulcerative Colitis Patients
Minguez, A.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1111. 2025
Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory Bowel Disease Patients
Aldars-Garcia, Laila; (...); Chaparro, Maria
Article. 10.1093/ibd/izad154. 2024
Short-term real-world effectiveness and safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: GRACE Study
Rodriguez-Lago, I.; (...); Cabriada, J. L.
Meeting Abstract. 2024
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.14309/ctg.0000000000000416. 2021
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review
Puig, Maria; (...); Domenech, Eugeni
Review. 10.3390/jcm12237366. 2023
Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2024
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
Article. 10.1093/ecco-jcc/jjae127. 2024
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.
Article. 10.3390/nu13061770. 2021
Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
Chaparro, M.; (...); ECCO CONFER Taskforce
Meeting Abstract. 2022
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]
Chaparro, Maria; (...); Julsgaard, Mette
Article. 10.1093/ecco-jcc/jjac050. 2022
Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU
Gros, B.; (...); Iglesias-Flores, E.
Meeting Abstract. 2024
Switching to standard-dose subcutaneous vedolizumab increases the percentage of patients in biochemical remission even in those intensified with intravenous vedolizumab: one year results of a Spanish multicentre observational study
Andres Pascual, L.; (...); Sicilia, B.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1000. 2025
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Telemonitoring with TECCU of active Inflammatory Bowel Disease is Not Inferior to Standard Care: Short-term Results of a Multicentre Randomized Controlled Trial of GETECCU.
Article. 10.2196/60966. 2024
Terapia de rescate con ciclosporina oral tras el uso de ustekinumab en colitis ulcerosa resistente a múltiples tratamientos.
Abia PL; (...); Niclós BB
Letter. 10.1016/j.gastrohep.2021.04.012. 2021
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
Ladron Abia, Pablo; (...); Iborra, Marisa
Article. 10.1016/j.gastrohep.2022.01.004. 2022
The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.
Gutierrez-Ontalvilla, P.; (...); Iborra, M.
Article. 10.1007/s00266-021-02718-1. 2022
The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making
Bastida Paz, Guillermo; (...); Nos, Pilar
Article. 10.1159/000531789. 2023
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response
Minguez, A.; (...); Nos, P.
Meeting Abstract. 2023
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Rodríguez-Moranta F; (...); Gutiérrez Casbas A
Practice Guideline. 10.1016/j.gastrohep.2024.01.007. 2024
Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
Ferreiro Iglesias, R.; (...); Barreiro-de Acosta, M.
Meeting Abstract. 2022
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
TREATMENT OF IRON DEFICIENCY WITHOUT ANEMIA WITH FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PROSPECTIVE EVALUATION OF CLINICAL AND PATIENT-REPORTED OUTCOMES IN SPAIN
Huguet, J. M.; (...); Munoz, M.
Meeting Abstract. 2022
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: Results from the VERNE study.
Bastida G; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2021.06.005. 2021
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
Gomez-Labrador, Celia; (...); Gisbert, Javier P
Article. 10.3390/pharmaceutics16050629. 2024
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU.
Mesonero F; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2024.09.023. 2024
Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Sard, M. Calafat; (...); Domenech, E.
Meeting Abstract. 2023
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
Manosa, Miriam; (...); Domenech, Eugeni
Article. 10.1016/j.dld.2022.07.013. 2022
Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2022
Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients
Mateos, B.; (...); Beltran, B.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
Variability in Mesalazine Management for Ulcerative Proctitis Include Doses, Route of Administration and Use of Fecal Calprotectin: Insights from Clinical Practice Across Spain Beyond Clinical Guidelines
Bastida Paz, G.; (...); Gonzalez-Lama, Y.
Meeting Abstract. 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens, Geert; (...); Laharie, David
Article. 10.1016/S2468-1253(24)00317-0. 2025